Early Signs Positive From FDA's Least-Burdensome Training
Executive Summary
An initial evaluation of US FDA's congressionally mandated staff training programs on "least burdensome" processes are promising, the agency says, but more time is needed to track data on more tangible positive impacts for device companies. Industry, meanwhile, will likely need more convincing.
You may also be interested in...
Least Burdensome Additional-Info Requests? US FDA Needs Metrics, GAO Says
The US Government Accountability Office says FDA needs more information to prove that is properly applying least-burdensome concepts for deficiency or additional-information letters sent to companies while reviewing pre-market submissions. FDA defends its performance, but plans to conduct more assessments.
'Least Burdensome' Supersized? Draft Guidance Outlines An Expanded View Of The US FDA Concept
The US agency issued a draft guidance that brings the 20-year old concept of "least burdensome" in medical device regulation to all corners of the device center's activities.
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.